Fig. 1

EVP signature for prognostic prediction CRLM survival. Quantification of EVPs from human serum samples A Boxplot analysis of EVP concentration in the discovery cohort. *: p ≤ 0.05, **: p ≤ 0.01. p values by Mann-Whitney U test. B Kaplan-Meier curve of overall survival for patients with EVP concentration before and after surgery in the discovery cohort. p values of two equal-sized parts according to the median of EVP concentration by log-rank test. C Boxplot analysis of EVP concentration in the total validation cohort including internal and external validation cohorts. *: p ≤ 0.05. p values by Mann-Whitney U test. D Kaplan-Meier curve of overall survival for patients with EVP concentration in the total validation cohort. p values of two equal-sized parts according to the median of EVP concentration by log-rank test. E Heatmap of 74 differentially expressed EVPs ( FDR<0.05 ). Each column represents an individual patient ( n_paired = 56 ) and each row represents an EVP. Labels of the right side represent pre-surgical survival associated proteins by Univariate cox analysis. *: p ≤ 0.05, **: p ≤ 0.01, ***: p ≤ 0.001, ****: p ≤ 0.0001. Bold labels are EVPs selected for generating an EVP signature. F-K EVP analysis for prognostic prediction CRLM survival: Top panel: Kaplan-Meier survival analysis was used to analyze survival of low-risk and high-risk groups based on the cut-off value of the risk score estimated from the discovery cohort. F Discovery cohort. G Internal validation cohort. H External validation cohort. p values by log-rank test. Bottom panel: Time-dependent Receiver operator characteristic (ROC) curves for the prognostic performance of the EVP signature in discovery cohort (I), internal validation cohort (J) and external validation cohort (K). 95%CI of AUC was marked by dotted line